Qin, Yu
Takahashi, Masamichi
Sheets, Kristopher
Soto, Horacio
Tsui, Jessica
Pelargos, Panayiotis
Antonios, Joseph P.
Kasahara, Noriyuki
Yang, Isaac
Prins, Robert M.
Braun, Jonathan
Gordon, Lynn K.
Wadehra, Madhuri
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1TR001881)
National Cancer Institute (R01 CA163971)
Oppenheimer Family Foundation
Richard and Barbara Braun
Visionary Fund Grant
Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research UCLA Scholars in Translational Medicine Program
Jason Dessel Memorial Seed Grant
UCLA Honberger Endowment Brain Tumor Research Seed Grant
Stop Cancer (US) Research Career Development Award
Gurtin SSCD and Skull Base Research Fellowship
Article History
Received: 21 November 2016
Accepted: 21 May 2017
First Online: 9 June 2017
Compliance with ethical standards
:
: M. W., L. K. G, and J. B. are inventors on the University of California patents related to the anti- EMP2 IgG1 antibody presented in this work. They are also founders of Paganini Biopharma. No other authors have competing interests.